1. Home
  2. SWTX vs CASH Comparison

SWTX vs CASH Comparison

Compare SWTX & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • CASH
  • Stock Information
  • Founded
  • SWTX 2017
  • CASH 1954
  • Country
  • SWTX United States
  • CASH United States
  • Employees
  • SWTX N/A
  • CASH N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • SWTX Health Care
  • CASH Finance
  • Exchange
  • SWTX Nasdaq
  • CASH Nasdaq
  • Market Cap
  • SWTX 2.2B
  • CASH 1.9B
  • IPO Year
  • SWTX 2019
  • CASH N/A
  • Fundamental
  • Price
  • SWTX $36.45
  • CASH $79.63
  • Analyst Decision
  • SWTX Strong Buy
  • CASH Hold
  • Analyst Count
  • SWTX 5
  • CASH 3
  • Target Price
  • SWTX $65.40
  • CASH $69.00
  • AVG Volume (30 Days)
  • SWTX 1.3M
  • CASH 206.6K
  • Earning Date
  • SWTX 11-12-2024
  • CASH 10-23-2024
  • Dividend Yield
  • SWTX N/A
  • CASH 0.25%
  • EPS Growth
  • SWTX N/A
  • CASH 10.60
  • EPS
  • SWTX N/A
  • CASH 6.62
  • Revenue
  • SWTX $135,487,000.00
  • CASH $712,044,000.00
  • Revenue This Year
  • SWTX $3,498.68
  • CASH N/A
  • Revenue Next Year
  • SWTX $98.08
  • CASH $5.04
  • P/E Ratio
  • SWTX N/A
  • CASH $12.03
  • Revenue Growth
  • SWTX N/A
  • CASH 10.60
  • 52 Week Low
  • SWTX $20.19
  • CASH $46.68
  • 52 Week High
  • SWTX $53.92
  • CASH $83.83
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 71.38
  • CASH 63.85
  • Support Level
  • SWTX $29.53
  • CASH $77.72
  • Resistance Level
  • SWTX $35.26
  • CASH $83.83
  • Average True Range (ATR)
  • SWTX 1.92
  • CASH 2.19
  • MACD
  • SWTX 0.74
  • CASH 0.54
  • Stochastic Oscillator
  • SWTX 87.38
  • CASH 71.58

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly-owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer, Commercial and Corporate Services/Other. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: